Tevogen Bio Holdings Inc. (TVGN)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 2,699,991 | |||
| General and administrative | 2,744,545 | |||
| Total operating expenses | 5,444,536 | |||
| Loss from operations | -5,444,536 | |||
| Interest (expense) income, net | -38,033 | |||
| Change in fair value of warrants | 21,410 | |||
| Merger transaction costs | - | |||
| Loss on issuance of commitment shares | - | |||
| Change in fair value of written call option derivative liabilities | - | |||
| Change in fair value of convertible promissory notes | - | |||
| Net (loss) income | -5,503,979 | |||
| Net (loss) income per share attributable to common stockholders, basic | -0.03 | |||
| Net loss per share attributable to common stockholders, diluted | -0.03 | |||
| Weighted-average common stock outstanding, basic | 184,307,169 | |||
| Weighted-average common stock outstanding, diluted | 184,307,169 | |||